Retatrutide’s Phase 3 trial results 2026
Retatrutide is set to transform the treatment of obesity and type 2 diabetes following groundbreaking results from its 2026 Phase 3 trials. Across four major studies, participants lost more than 24 per cent of their body weight on average, a result comparable to that of bariatric surgery, which is currently the most effective weight loss option.